CDMO– tag –
-
KOLON Biotech Expands Comprehensive CDMO Services in Korea, Specializing in Cell, Gene, and Exosome Therapies
MTEC South Korea Overview KOLON Biotech in South Korea is bolstering its capabilities as a specialized Contract Development and Manufacturing Organization (CDMO) for advanced cell, gene, and exosome therapies. The company offers end-to-e... -
Lonza Launches ‘RaMP’ Service, Accelerating Custom Media Supply to 10 Business Days for Early Bioprocess Development
Manufacturing Chemist Switzerland Overview Lonza has launched its Rapid Custom Media Prototyping (RaMP) service to significantly accelerate early bioprocess development. This new offering allows biopharmaceutical companies to receive cus... -
4basebio and Genezen Partnership Revolutionizes Viral Vector Manufacturing: Cell-Free Synthetic DNA Reduces Costs by 30%
BioPharm International USA Overview 4basebio and viral vector CDMO Genezen announced a partnership to integrate 4basebio's cell-free hpDNA platform into Genezen's manufacturing workflow. This innovative technology enzymatically produces ... -
KOLON Biotech Boosts End-to-End CDMO Services for Advanced Cell, Gene, and Exosome Therapies in South Korea
MTEC South Korea Overview South Korea's KOLON Biotech is enhancing its comprehensive CDMO services, specializing in advanced cell, gene, and exosome therapies. The company offers end-to-end solutions, from technology transfer and process... -
Samsung Biologics Announces KRW 3 Trillion ($2.18B) Rights Offering to Fund PolyPeptide Group Acquisition and Bio Campus II Expansion, Strengthening CDMO Leadership
PR Newswire South Korea Overview Samsung Biologics has announced a substantial KRW 3 trillion (approximately $2.18 billion) rights offering to finance its acquisition of PolyPeptide Group and the expansion of its Bio Campus II. This stra... -
Piramal Pharma Acquires Additional 40.67% Stake in Yapan Bio; Curium Announces ~$8 Billion Acquisition of Lantheum
Pharmaceutical Technology Global Overview Indian pharmaceutical services group Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio, a Hyderabad-based CDMO specializing in vaccines and biopharmaceuticals, strengthening its... -
Biopharma M&A Surges in H1 2026, Led by Sun Pharma’s $11.75B Organon Acquisition and Merck KGaA’s $11.3B Bio-Techne Deal
Herbert Smith Freehills Kramer Global Overview The first half of 2026 witnessed a significant resurgence in pharmaceutical M&A activity, with several major acquisitions driving market consolidation. Notable transactions include Sun P... -
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
Samsung Biologics Expands to 845,000L Capacity with GSK Facility Acquisition; Lonza, Resilience Announce Major Investments Amidst CDMO Restructuring
DCAT Value Chain Insights USA, South Korea, Switzerland Overview The CDMO industry is undergoing unprecedented restructuring in 2026, driven by major strategic investments and M&A activities by leading players. Samsung Biologics acqu... -
Biologics CDMO Market to Reach $38.29 Billion by 2031, Fill-Finish Emerging as Key Segment
GlobeNewswire Global Overview This article provides an overview of a market research report from GlobeNewswire. The Biologics CDMO market is projected to grow from $27.13 billion in 2026 to $38.29 billion by 2031, exhibiting a CAGR of 7....
